RT Journal Article
T1 Negative predictive value of procalcitonin to rule out bacterial respiratory co-infection in critical covid-19 patients.
A1 Carbonell, Raquel
A1 Urgelés, Silvia
A1 Salgado, Melina
A1 Rodríguez, Alejandro
A1 Reyes, Luis Felipe
A1 Fuentes, Yuli V
A1 Serrano, Cristian C
A1 Caceres, Eder L
A1 Bodí, María
A1 Martín-Loeches, Ignacio
A1 Solé-Violán, Jordi
A1 Díaz, Emili
A1 Gómez, Josep
A1 Trefler, Sandra
A1 Vallverdú, Montserrat
A1 Murcia, Josefa
A1 Albaya, Antonio
A1 Loza, Ana
A1 Socias, Lorenzo
A1 Ballesteros, Juan Carlos
A1 Papiol, Elisabeth
A1 Viña, Lucía
A1 Sancho, Susana
A1 Nieto, Mercedes
A1 Del, M
A1 Lorente, Carmen
A1 Badallo, Oihane
A1 Fraile, Virginia
A1 Arméstar, Fernando
A1 Estella, Angel
A1 Abanses, Paula
A1 Sancho, Isabel
A1 Guasch, Neus
A1 Moreno, Gerard
A1 COVID-19 SEMICYUC Working Group and the LIVEN-Covid-19 Investigators, 
K1 Bacterial co-infection
K1 C-reactive protein
K1 Covid-19 pneumonia
K1 Mortality
K1 Procalcitonin
AB Procalcitonin (PCT) and C-Reactive Protein (CRP) are useful biomarkers to differentiate bacterial from viral or fungal infections, although the association between them and co-infection or mortality in COVID-19 remains unclear. The study represents a retrospective cohort study of patients admitted for COVID-19 pneumonia to 84 ICUs from ten countries between (March 2020-January 2021). Primary outcome was to determine whether PCT or CRP at admission could predict community-acquired bacterial respiratory co-infection (BC) and its added clinical value by determining the best discriminating cut-off values. Secondary outcome was to investigate its association with mortality. To evaluate the main outcome, a binary logistic regression was performed. The area under the curve evaluated diagnostic performance for BC prediction. 4635 patients were included, 7.6% fulfilled BC diagnosis. PCT (0.25[IQR 0.1-0.7] versus 0.20[IQR 0.1-0.5]ng/mL, p These biomarkers at ICU admission led to a poor ability to predict BC among patients with COVID-19 pneumonia. Baseline values of PCT
YR 2022
FD 2022-06-30
LK http://hdl.handle.net/10668/22321
UL http://hdl.handle.net/10668/22321
LA en
DS RISalud
RD Apr 11, 2025